StockData
Alkermes plc. logo

Alkermes plc. (ALKS) stock

ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30208% above fair value
$46.85+1.40 (+3.08%)

Close on Nov 18, 2026Market cap $7.86BP/E 123.3Yield –

Alkermes free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Alkermes's free cash flow for the twelve months ending Jun 30, 2026 was $221.65M, down 53.8% year over year. For fiscal 2025 it was $480.33M, up 18.4% from the year before. The highest annual figure on record is $480.33M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$480.33M+18.4%
FY2024Dec 31, 2024$405.64M+14.8%
FY2023Dec 31, 2023$353.31M–
FY2022Dec 31, 2022-$17.21M-123.4%
FY2021Dec 31, 2021$73.70M+81.4%
FY2020Dec 31, 2020$40.62M–
FY2019Dec 31, 2019-$18.87M-163.2%
FY2018Dec 31, 2018$29.85M–
FY2017Dec 31, 2017-$32.11M–
FY2016Dec 31, 2016-$107.46M–
FY2015Dec 31, 2015-$93.24M-189.4%
FY2013Mar 31, 2013$104.33M–
FY2012Mar 31, 2012-$19.47M–
FY2011Mar 31, 2011-$15.31M–
FY2010Mar 31, 2010-$28.03M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$137.04M-0.1%
Q1 FY2026Mar 31, 2026-$169.83M-291.5%
Q4 FY2025Dec 31, 2025$170.09M-5.8%
Q3 FY2025Sep 30, 2025$84.36M+15.0%
Q2 FY2025Jun 30, 2025$137.19M-1.2%
Q1 FY2025Mar 31, 2025$88.70M+594.8%
Q4 FY2024Dec 31, 2024$180.62M+100.2%
Q3 FY2024Sep 30, 2024$73.33M-14.0%
Q2 FY2024Jun 30, 2024$138.92M-32.6%
Q1 FY2024Mar 31, 2024$12.77M–
Q4 FY2023Dec 31, 2023$90.21M–
Q3 FY2023Sep 30, 2023$85.26M–
Q2 FY2023Jun 30, 2023$206.01M–
Q1 FY2023Mar 31, 2023-$28.16M-302.8%
Q4 FY2022Dec 31, 2022-$8.98M-140.2%
Q3 FY2022Sep 30, 2022-$9.85M-112.6%
Q2 FY2022Jun 30, 2022-$12.27M-146.3%
Q1 FY2022Mar 31, 2022$13.89M–
Q4 FY2021Dec 31, 2021$22.36M-63.9%
Q3 FY2021Sep 30, 2021$77.96M+44.9%
Q2 FY2021Jun 30, 2021$26.50M–
Q1 FY2021Mar 31, 2021-$53.13M–
Q4 FY2020Dec 31, 2020$61.90M+512.9%
Q3 FY2020Sep 30, 2020$53.80M+366.1%
Q2 FY2020Jun 30, 2020-$15.01M–
Q1 FY2020Mar 31, 2020-$60.07M–
Q4 FY2019Dec 31, 2019$10.10M-76.5%
Q3 FY2019Sep 30, 2019$11.54M-32.3%
Q2 FY2019Jun 30, 2019-$39.08M-357.3%
Q1 FY2019Mar 31, 2019-$1.43M–
Q4 FY2018Dec 31, 2018$42.92M+137.3%
Q3 FY2018Sep 30, 2018$17.06M+156.4%
Q2 FY2018Jun 30, 2018$15.19M–
Q1 FY2018Mar 31, 2018-$45.32M–
Q4 FY2017Dec 31, 2017$18.09M–
Q3 FY2017Sep 30, 2017$6.65M+106.3%
Q2 FY2017Jun 30, 2017-$33.73M–
Q1 FY2017Mar 31, 2017-$23.13M–
Q4 FY2016Dec 31, 2016-$2.31M–
Q3 FY2016Sep 30, 2016$3.23M–

More Alkermes figures

See a number that looks wrong?